12:00 AM
May 04, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ciclesonide nasal aerosol: Preliminary Phase III data

Preliminary data from a double-blind trial in 707 adult and adolescent patients >=13 years old showed that 80 or 160 ug/day Omnaris HFA met the primary endpoint of significantly reducing the 24-hour reflective TNSS vs. placebo (p<0.0001 for both). Both doses also met...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >